# US 2015/0105384 A1 · Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105384 A1
- Document ID: US20150105384A1
- Status: Published application
- Kind: A1
- Application number: 14/510,711
- Filed: 2014-10-09
- Published: 2015-04-16
- Earliest claimed: 2013-10-10
- Assignees: Acetylon Pharmaceuticals, Inc.
- Inventors: Simon Stewart Jones; Min Yang; David Lee Tamang
- Web page: https://patentgrep.com/patent/US20150105384A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein,
Rx is selected from the group consisting of C1-6-alkyl, C1-6-alkoxy, halo, —OH, —C(O)R1, —CO2R1, —C(O)N(R1)2, aryl, —C(S)N(R1)2, and S(O)2R1, wherein aryl may be optionally substituted by one or more groups selected from C1-6-alkyl, C1-6-alkoxy, —OH, halo, and haloalkyl;
Ry is selected from the group consisting of H, C1-6-alkyl, C1-6-alkoxy, halo, —OH, —C(O)R1, —CO2R1, and —C(O)N(R1)2;
Rz is selected from the group consisting of C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, C3-8-cycloalkyl, C3-7-heterocycloalkyl, aryl, and heteroaryl, each of which may be optionally substituted by C1-6-alkyl, C1-6-alkoxy, halo, or —OH; and
each R1 is, independently for each occurrence, selected from the group consisting of H, C1-6-alkyl, C3-8-cycloalkyl, C3-7-heterocycloalkyl, aryl, heteroaryl, C1-6-alkyl-cycloalkyl, C1-6-alkyl-heterocycloalkyl, C1-6-alkyl-aryl, and C1-6-alkyl-heteroaryl, wherein C3-8-cycloalkyl, C3-7-heterocycloalkyl, aryl, heteroaryl, C1-6-alkyl-cycloalkyl, C1-6-alkyl-heterocycloalkyl, C1-6-alkyl-aryl, and C1-6-alkyl-heteroaryl may be optionally substituted by one or more groups selected from C1-6-alkyl, C1-6-alkoxy, —OH, halo, and haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
Rx is independently selected from the group consisting of aryl, —C(O)R1, —CO2R1, —C(O)N(R1)2, —C(S)N(R1)2, and S(O)2R1;
Ry is selected from the group consisting of H, C1-6-alkyl, or, halo; and
Rz is selected from the group consisting of C1-6-alkyl, C3-8-cycloalkyl, C3-7-heterocycloalkyl, aryl, and heteroaryl.

### Claim 3 (depends on 1, 2)

The compound of any one of claims 1-2, wherein Rz is C1-6-alkyl or aryl.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Rz is isopropyl or methyl.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3, wherein Rz is phenyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The compound of any of claims 1-5, wherein Rx is —C(O)NHR1.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The compound of any of claims 1-5, wherein Rx is —C(O)R1 or —CO2R1.

### Claim 8 (depends on 1, 2, 3, 4, 5)

The compound of any of claims 1-5, wherein Rx is —C(S)NHR1 or S(O)2R1.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein at least one of R1 is selected from the group consisting of C1-6-alkyl, aryl, C1-6-alkyl-aryl and C1-6-alkyl-heteroaryl, wherein aryl, C1-6-alkyl-aryl and C1-6-alkyl-heteroaryl may be optionally substituted by one or more groups selected from C1-6-alkyl, C1-6-alkoxy, —OH, halo, and haloalkyl.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein at least one of R1 is —CH3, —CH2CH3, phenyl, —CH2-phenyl, or —CH2-indolyl, wherein phenyl, —CH2-phenyl, or —CH2-indolyl may be optionally substituted by one or more groups selected from C1-6-alkyl or halo.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein at least one of R1 is phenyl, and wherein phenyl is optionally substituted by one or more groups selected from C1-6-alkyl, C1-6-alkoxy, halo, and haloalkyl.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of claim any one of claims 1-11, wherein Ry is H.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, selected from the following:
or pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of inhibiting the activity of HDAC1, HDAC2, and HDAC6 in a subject in need thereof comprising administering to the subject a compound of any one of claims 1-13 or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A method of selectively inhibiting the activity of HDAC1, HDAC2, and HDAC6 over other HDACs in a subject in need thereof comprising administering to the subject a compound of any one of claims 1-13 or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 16)

The method of claim 16, wherein the compound of any one of claims 1-13 has a selectivity for HDAC1, HDAC2, and HDAC6 when tested in a HDAC enzyme assay of about 2 to 1000 fold greater than for other HDACs.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating a disease mediated by one or more HDACs in a subject in need thereof comprising administering to the subject a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 14.

### Claim 19 (depends on 18)

The method of claim 18, wherein the HDACs are HDAC1 and HDAC2.

### Claim 20 (depends on 18)

The method of claim 18, wherein the HDAC is HDAC6.

### Claim 21 (depends on 18)

The method of claim 18, wherein the disease is a hemoglobinopathy.

### Claim 22 (depends on 18)

The method of claim 18, wherein the disease is sickle-cell disease.

### Claim 23 (depends on 18)

The method of claim 18, wherein the disease is beta-thalassemia.

### Claim 24 (depends on 18)

The method of claim 18, wherein the disease is a neurodegenerative disease.

### Claim 25 (depends on 24)

The method of claim 24, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, frontotemporal lobe dementia, progressive supranuclear palsy, corticobasal dementia, Parkinson's disease, Huntington's disease, amytrophic lateral sclerosis, Charcot-Marie-Tooth disease and peripheral neuropathy.

### Claim 26 (depends on 18, 19, 20)

The method of any one of claims 18-20, wherein the disease is a cancer or a proliferation disease.

### Claim 27 (depends on 26)

The method of claim 26, wherein the cancer is selected from the group consisting of lung cancer, colon and rectal cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, kidney cancer, ovarian cancer, stomach cancer, skin cancer, bone cancer, gastric cancer, breast cancer, glioma, glioblastoma, neuroblastoma, hepatocellular carcinoma, papillary renal carcinoma, head and neck squamous cell carcinoma, leukemia, lymphomas, myelomas, retinoblastoma, cervical cancer, melanoma and/or skin cancer, bladder cancer, uterine cancer, testicular cancer, esophageal cancer, and solid tumors.

### Claim 28 (depends on 26)

The method of claim 26, wherein the cancer is lung cancer, colon cancer, breast cancer, leukemia, or a lymphoma.

### Claim 29 (depends on 26)

The method of claim 26, wherein the cancer is neuroblastoma.

### Claim 30 (depends on 26)

The method of claim 26, wherein the cancer is non-small cell lung cancer (NSCLC).

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of treating a subject suffering from or susceptible to Hodgkin's lymphoma comprising administering to a subject a therapeutically effective amount of a compound of any one of claims 1-13, or the pharmaceutical composition of claim 14, to thereby treat the subject suffering from or susceptible to Hodgkin's lymphoma.

### Claim 32 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 15-31, wherein the subject is a human.

### Claim 33

A method for inhibiting migration of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 34

A method for inducing maturation of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 35

A method for altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 36

A method for decreasing viability and survival of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 37

A method for inducing differentiation of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 38

A method for enhancing low-concentration ATRA treatment of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 39

A method for inducing cell cycle arrest of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 33-39, wherein the inhibitor is selected from the group consisting of a compound of Formula I, Formula II, Formula III, Compound 001, Compound X, Compound Y, or any of the compounds in Table 1.

### Claim 41 (depends on 40)

The method of claim 40, wherein the inhibitor is either Compound 001 or Compound X or Compound Y.

### Claim 42

A method for treating neuroblastoma in a subject comprising administering to the subject a therapeutically effective amount of Compound 001, Compound X, or Compound Y.
